Surrozen (SRZN) Net Cash Flow (2020 - 2026)
Surrozen (SRZN) recorded quarterly Net Cash Flow of $17.7 million in Q1 2026, up 124.23% quarter-over-quarter from $7.9 million in Q4 2025, and down 73.66% on a YoY basis from $67.1 million in Q1 2025.
Surrozen (SRZN) Net Cash Flow (2020 - 2026) Analysis & Trends
Surrozen's Net Cash Flow history runs 7 years deep, the most recent figure standing at $17.7 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 73.66% year-over-year to $17.7 million; the TTM figure through Mar 2026 stood at $5.3 million (down 92.89% YoY), while the FY2025 annual figure was $54.7 million, up 3871.03% from the prior year.
- Net Cash Flow was $17.7 million for Q1 2026 at Surrozen, up from $7.9 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $67.1 million in Q1 2025 to a low of -$18.8 million in Q1 2022.
- Historically, Net Cash Flow has averaged $4.4 million across 5 years, with a median of $2.6 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow tumbled 379.16% in 2024, then soared 870.17% in 2025.
- A 5-year view of Net Cash Flow shows it stood at -$796000.0 in 2022, then jumped by 394.1% to $2.3 million in 2023, then surged by 52.97% to $3.6 million in 2024, then soared by 119.99% to $7.9 million in 2025, then jumped by 124.23% to $17.7 million in 2026.
- The last three Net Cash Flow figures came in at $17.7 million (Q1 2026), $7.9 million (Q4 2025), and -$9.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.44 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 664,983.53 |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | 17.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.67 Mn |
| Mar 31, 2026 | 17.67 Mn |
| Dec 31, 2025 | 7.88 Mn |
| Dec 31, 2025 | 7.88 Mn |
| Sep 30, 2025 | -9.02 Mn |
| Sep 30, 2025 | -9.02 Mn |
| Jun 30, 2025 | -11.24 Mn |
| Jun 30, 2025 | -11.24 Mn |
| Mar 31, 2025 | 67.06 Mn |
| Mar 31, 2025 | 67.06 Mn |
| Dec 31, 2024 | 3.58 Mn |
| Dec 31, 2024 | 3.58 Mn |
| Sep 30, 2024 | -6.75 Mn |
| Sep 30, 2024 | -6.75 Mn |
| Jun 30, 2024 | 10.43 Mn |
| Jun 30, 2024 | 10.43 Mn |
| Mar 31, 2024 | -8.71 Mn |
| Mar 31, 2024 | -8.71 Mn |
| Dec 31, 2023 | 2.34 Mn |
| Dec 31, 2023 | 2.34 Mn |